Bristol-Myers Squibb was handed a defeat in a patent lawsuit, which will allow generic drugmaker MylanLaboratories (nyse: MYL - news - people) to make a lower-cost version of BuSpar, Bristol's fifth best-selling drug.
Four years ago, the provost and business school dean at West Virginia University resigned after an investigation found an executive MBA was improperly awarded to Heather Bresch who, at the time, was chief operating officer at MylanLaboratories.